Author: Nathan

Most Shorted ASX Stocks 5/11/25

The top 20 ASX companies with the highest short-sold positions

Most Shorted ASX Stocks 5/11/25 - top 20 list

General observations comparing today to 9 months ago

  • 8 stocks remain in the top 20 today that were in the top 20 back then.
  • Themes remain similar
    • In Feb there were 3 Uranium stocks in the top 20. Today there are still 3.
    • In Feb there were 3 Lithium stocks. Today there are still 3.
    • In Feb there was a silver stock, a gold stock, a rare earths stock, a graphite stock and an oil stock. Resources have been recovering over the last 3 or so months As a result, Iluka (mineral sands) is the only other resource stock in the top 20 today.
    • There are more fallen angle style industrial stocks in the top 20.
    • A new theme has emerged: Healthcare stocks of which there are now 4 in the top 20 today. Nevertheless, I would still put these in the “fallen angels” category.

A look at the 8 stocks that remain in the list

  1. Boss Energy

Most Shorted ASX Stocks 5/11/25 - BOE price and short position charts

BOE Red flag analysis

2. Palladin Energy

Most Shorted ASX Stocks 5/11/25 - PDN price and short position charts

PDN Red flag analysis

3. Dominos Pizza

Most Shorted ASX Stocks 5/11/25 - DMP price and short position charts

DMP Red flag analysis

4. Pilbara Minerals

Most Shorted ASX Stocks 5/11/25 - PLS price and short position charts

PLS Red flag analysis

5. IDP Education

Most Shorted ASX Stocks 5/11/25 - IEL price and short position charts

IEL Red flag analysis

6. Corporate Travel Group

Most Shorted ASX Stocks 5/11/25 - CTD price and short position charts

CTD Red flag analysis

7. Lifestyle Communities

Most Shorted ASX Stocks 5/11/25 - LIF price and short position charts

LIC Red flag analysis

8. Mineral Resources

Most Shorted ASX Stocks 5/11/25 - MIN price and short position charts

MIN Red flag analysis


A look at some of the stocks that are no longer on the list

  1. Syrah Resources

Most Shorted ASX Stocks 5/11/25 - SYR price and short position charts

SYR Red flag analysis

2. Deep Yellow

Most Shorted ASX Stocks 5/11/25 - DYL price and short position charts

DYL Red flag analysis

3. Star Entertainment Group

Most Shorted ASX Stocks 5/11/25 - SGR price and short position charts

4. Megaport

Most Shorted ASX Stocks 5/11/25 - MP1 price and short position charts

MP1 Red flag analysis

5. Lynas

Most Shorted ASX Stocks 5/11/25 - LYC price and short position charts

LYC Red flag analysis


A look at some recent additions

  1. Guzman Y Gomez

Most Shorted ASX Stocks 5/11/25 - GYG price and short position charts

GYG Red flag analysis

2. Telix Pharmaceuticals

Most Shorted ASX Stocks 5/11/25 - TLX price and short position charts

TLX Red flag analysis

3. Digico Infrastructure

Most Shorted ASX Stocks 5/11/25 - DGT price and short position charts

DGT Red flag analysis


Conclusion

The conclusions I reached in February 2025 still hold. Troubled resource names and fallen angels continue to dominate the most-shorted list. Overlaying my red-flag checks shows that almost every heavily shorted stock has multiple fundamental issues—declining earnings, high debt, margin compression, and/or stretched valuations. This isn’t market manipulation or predatory behaviour; it’s weak fundamentals. In most cases, the rationale for heavy short interest is as straightforward as the rationale for strong buying in companies delivering consistent growth.


Disclaimer: This information is provided purely for educational purposes. It takes no account of an individual’s personal financial circumstances and hence can in no way constitute financial advice. The above data may be subject to errors or inconsistencies for which the author takes no liability. It is imperative that all investors do their own research or if they need advice, seek it from a qualified financial adviser.

Most Shorted ASX Stocks 5/11/25

Tabcorp Holdings (ASX:TAH) 2025 AGM Presentation Summary

October 2025 | Website: https://www.tabcorp.com.au

Overall Report Tone

Tabcorp Holdings (ASX: TAH) delivered a substantial turnaround in FY25, showing strong revenue and earnings growth, improved operational efficiency, and a clear execution strategy to become a structurally profitable omnichannel wagering business. Management expressed confidence and momentum heading into FY26, driven by strategic reforms, leadership renewal, and continued investment in digital and customer safety capabilities.


📊 Financial Results Summary (FY25 vs FY24)

Metric FY25 FY24 % Change
💰 Revenue $2,614.6M $2,338.9M +11.8%
📈 Variable Contribution $1,088.7M $931.7M +16.9%
💸 Operating Expenses (Opex) ($697.2M) ($614.0M) -13.6%
💼 EBITDA $391.5M $317.7M +23.2%
🧮 EBIT $188.7M $97.4M +93.7%
🧾 NPAT (before significant items) $49.5M $28.0M +76.8%
📉 Statutory NPAT $36.6M ($1,359.7M) Turnaround
💵 Adjusted EPS 3.9 cps Not disclosed >100%
💰 Dividend (unfranked) 2.0 cps 1.3 cps +54%
📉 Net Debt to EBITDA 1.6x Not disclosed ✅ Below 2.5x target

🆕 New Information Disclosed

🐎 Successful transition to new Victorian Wagering Licence, contributing ~$84M in EBITDA uplift over 10.5 months.
🧠 New AI-powered player monitoring tool to be deployed in FY26 to enhance real-time intervention and customer safety.
🧱 Restructuring implemented: 230 roles removed, vertical integration applied, tighter P&L accountability introduced.
🧑‍💼 New leadership team onboarded with capability in wagering, digital, legal, operations, and compliance.
🏇 TAB Takeover and TAB Time delivering brand impact across racing carnivals and Saturday venues.
📺 Strategic focus on retail innovation, Sky Media, and the MAX network, targeting an integrated omnichannel experience.


✅ Positive Surprises or Potential Concerns

  • 📈 NPAT grew 77% and EBIT nearly doubled, showing strong operational leverage.

  • 🧠 Cost discipline resulted in opex down 2.4%, ahead of target — margin-accretive execution.

  • 💡 New strategic clarity: Five-pillar framework offers structured growth roadmap with stakeholder alignment.

  • ⚠️ Transformation costs ($27.1M) and lack of franking capacity (due to tax refund) could weigh on short-term perceptions.


📉 Results vs Market Expectations

  • 🎯 Earnings well above prior year and likely ahead of market expectations post-restructure and demerger impact.

  • ✅ FY25 marks a clear pivot from turnaround to execution, with FY26 now expected to reflect full Victorian Licence benefit.

  • 🔍 Investor focus shifting from survival to scalability and profitability, helped by strong media and digital assets.

  • Franking credit absence (due to FY24 ATO refunds) limits full income yield for some investors.


🔮 Outlook and Guidance Statements

  • 🔄 FY26 to focus on operationalising strategy and delivering full-year uplift from Victorian licence.

  • 🔄 Continued investment in AI and customer protection, with new monitoring tools and enhanced Safer Gambling team.

  • 🧭 Long-term goal to deliver structural profitability in retail and leadership in national tote reform.

  • 💼 Media growth and asset integration (Sky, Tote, MAX) set to differentiate offering in sports and racing entertainment.


Tabcorp Holdings (ASX:TAH) 2025 AGM Presentation Summary - 12 month share price chart with 3EMA and volume indicators


Disclaimer: This information is provided purely for educational purposes. It takes no account of an individual’s personal financial circumstances and hence can in no way constitute financial advice. The above data may be subject to errors or inconsistencies for which the author takes no liability. It is imperative that all investors do their own research or if they need advice, seek it from a qualified financial adviser.

Tabcorp Holdings (ASX:TAH) 2025 AGM Presentation Summary

Kinatico (ASX:KYP) 2025 AGM Presentation Summary

October 2025 | Website: https://www.kinatico.com

Overall Report Tone

The Q1 FY26 update from Kinatico (ASX: KYP) signals strong operational momentum, driven by accelerating SaaS revenue growth and improved profitability, all while maintaining a debt-free balance sheet. The company’s strategic focus on small to medium business (SMB) markets and the launch of its compliance marketing initiative (“KC”) underline its transition into a higher-margin, scalable SaaS-driven growth model.


📊 Financial Results Summary (Q1 FY26 vs Q1 FY25)

Metric Q1 FY26 Q1 FY25 % Change
💰 Consolidated Revenue $9.1M $8.0M +13%
💻 SaaS Revenue $4.8M $3.0M +58%
📊 SaaS % of Total Revenue 53% 38% ↑ by 15pp
📈 Annualised SaaS Revenue $19.2M $12.1M +58%
🏦 EBITDA $1.4M $1.2M +21%
📉 Net Debt $0 $0 No change

🆕 New Information Disclosed

🔹 “KC” Compliance Platform has been soft-launched with 7 early signups even before marketing begins — a new initiative aimed at the SMB compliance market.
🔹 Marketing investment into KC includes print, digital, social, podcast, and streaming ads, signalling a full-scale go-to-market push.
🔹 Clear dual-track strategy revealed: SMB (volume + self-service) and Mid/Enterprise (ACV + expansion potential).
🔹 First signs of international growth plans: focus on New Zealand and Southeast Asia.
🔹 Company is pushing the narrative of growing AND remaining profitable through automation, margin expansion, and scalability.


✅ Positive Surprises or Potential Concerns

  • 💡 +58% SaaS revenue growth with SaaS now over half of total revenue indicates a rapid and healthy business model transition.

  • 🐶 Launch of KC (Kelpie character) is a bold and differentiated marketing initiative — unique in B2B RegTech space.

  • 💪 EBITDA margins expanded despite growth investment, showing disciplined cost management.

  • 🚫 No mention of cash flow, EPS or dividend, which may be a concern for income-focused investors.


📉 Results vs Market Expectations

  • 📈 Revenue and EBITDA growth exceed typical expectations for a microcap SaaS business — particularly with no debt.

  • 🤖 The platform appears ready to scale, with investment into automation and unit economics already paying off.

  • 🚀 Marketing activity implies confidence in demand, with 7 early adopters signed pre-launch.

  • 🔍 Investors may note the lack of full financials (no EPS or cash flow), making full analysis more difficult.


🔮 Outlook and Guidance Statements

  • 🎯 Company expects to scale profitably, balancing investment in KC with margin discipline.

  • 🌏 International expansion planned after AU/NZ success — SEA markets cited as next logical step.

  • 🛠 Continued emphasis on automation and tech enablement to support margin expansion.

  • 📈 Strong statements of ongoing EBITDA growth, with self-funded reinvestment a key theme.


Kinatico (ASX:KYP) 2025 AGM Presentation Summary - 12 month daily price chart with 3EMA and volume indicators


Disclaimer: This information is provided purely for educational purposes. It takes no account of an individual’s personal financial circumstances and hence can in no way constitute financial advice. The above data may be subject to errors or inconsistencies for which the author takes no liability. It is imperative that all investors do their own research or if they need advice, seek it from a qualified financial adviser.

Kinatico (ASX:KYP) 2025 AGM Presentation Summary

FY25 Results Season Performances

Baby Bunting (BBN)

Sector: Consumer Cyclical | Industry: Specialty Retail

Baby Bunting Group Limited is Australia’s largest specialty retailer of baby goods, offering a comprehensive range of products and services for infants and parents.

BBN Broker Price Target: $2.74 (previous $1.775) – BUY


Tabcorp (TAH)

Sector: Consumer Cyclical | Industry: Gambling

Tabcorp Holdings Limited is a diversified gambling entertainment company, operating wagering, media, and gaming services across Australia, including TAB, Sky Racing, and Keno brands.

  • 2025 PER 25.4 | 2026e PER 33.8

TAH Broker Price Target: $0.96 (previous $0.82) – BUY


ZIP Co (ZIP)

Sector: Financial Services | Industry: Credit Services

Zip Co Limited is a financial technology company providing buy now, pay later services, allowing consumers to make purchases and pay over time, operating across various markets globally.

ZIP Broker Price Target: $4.48  (previous $3.46) – STRONG BUY


Life360 (360)

Sector: Technology | Industry: Software – Application

Life360, Inc. is a technology company specializing in location-based services through its Life360 mobile app, which offers features like location sharing, driving safety, and emergency assistance. The company also provides hardware tracking devices through its Tile product line, enabling users to locate lost items.

360 Broker Price Target: $47.27  (previous $27.30) – BUY


Eagers Automotive (APE)

Sector: Consumer Cyclical | Industry: Auto & Truck Dealerships

Eagers Automotive Limited is Australia’s largest automotive retail group, operating a network of dealerships across the country. The company offers a wide range of new and used vehicles, along with related services such as financing, insurance, and parts distribution.

APE Broker Price Target: $24.05  (previous $12.16) – NEUTRAL


Lovisa Holdings (LOV)

Sector: Consumer Cyclical | Industry: Specialty Retail

Lovisa Holdings Limited is a fast-fashion jewelry retailer, operating stores across Australia and internationally, offering a range of affordable jewelry and accessories.

LOV Broker Price Target: $24.05  (previous $12.16) – NEUTRAL


Netwealth Group (NWL)

Sector: Technology | Industry: Software – Application

Netwealth Group Limited offers investment and superannuation platform solutions, providing financial intermediaries and investors with a range of portfolio administration and management services.

NWL Broker Price Target: $34.50  (previous $28.09) – NEUTRAL


Aussie Broadband (ABB)

Sector: Communication Services | Industry: Telecom Services

Aussie Broadband Limited is an Australian telecommunications company providing internet, mobile, and other related services to residential, business, and government customers. Founded in 2003 and based in Morwell, Australia, it offers broadband, voice, and managed network solutions across the nation.

ABB Broker Price Target: $5.87  (previous $3.99) – BUY


The A2 Milk Company (A2M)

Sector: Consumer Defensive | Industry: Packaged Foods

The a2 Milk Company Limited specializes in the sale of branded milk and related products containing only the A2 protein type, catering to consumers in Australia, New Zealand, China, and the United States. Their product line includes liquid milk, infant formula, and other dairy products under the a2 Milk and a2 Platinum brands.

A2M Broker Price Target: $8.13  (previous $6.17) – NEUTRAL


CSL (CSL)

Sector: Healthcare | Industry: Biotechnology

CSL Limited is a global biotechnology company that develops and delivers innovative biotherapies and influenza vaccines, improving the health of people worldwide.

CSL Broker Price Target: $284.7  (previous $319.08) – BUY

James Hardie Industries (JHX)

Sector: Basic Materials | Industry: Building Materials

James Hardie Industries plc (ASX:JHX) manufactures and sells fiber cement and gypsum products for building applications like siding and cladding. They operate in North America, Asia Pacific, and Europe with brands like HardiePlank.

JHX Broker Price Target: $33.95  (previous $54.10) – BUY


Woolworths Group (WOW)

Sector: Consumer Defensive | Industry: Grocery Stores

Woolworths Group Limited (ASX:WOW) operates supermarkets in Australia and New Zealand under Woolworths, Metro, and Countdown brands, alongside discount retailer Big W and Petstock for pet supplies. It also supports online retail and B2B food supply services.

WOW Broker Price Target: $30.32  (previous $34.99) – NEUTRAL


Your Stock Requests

Island Pharmaceuticals (ILA)

  • Micro-cap antiviral repurposing biotech. Lead asset ISLA-101 (a repurposed small-molecule) is being developed for dengue fever using a human challenge model; strategy is faster, lower-risk development by starting with known safety profiles.
  • Positive Phase 2a/b top-line results (12 Jun 2025). Company reported clinically meaningful anti-dengue activity: reduced viremia and symptoms in the prophylactic cohort; a treatment-cohort drug signal; presentation with additional findings followed on 17 Jun. These results are the primary driver of recent interest.
  • June QTR Cash flow report: Revenue $0 | OCF -$823K | Cash on hand: $7.3M | No debt

Race Oncology (RAC)

  • Clinical-stage oncology company developing RC220 (bisantrene), a reformulated anthracene-derived agent pitched for two things: anticancer activity and cardio-protection when combined with doxorubicin (a standard chemo that’s cardiotoxic).
  • Phase 1 combo trial is live and recruiting: first patient safely dosed on 19 Jun 2025 in Australia; Hong Kong sites (Queen Mary, Prince of Wales) received ethics approvals in July and activation commenced in early September with screening underway. These steps de-risk execution and tend to be trading catalysts for small-cap biotech.
  • June QTR Cash flow report: Revenue $0 | OCF -$3.5M | Cash on hand: $13.7M | No debt

4DMedical (4DX)

  • Respiratory imaging software that quantifies lung ventilation/perfusion from standard scans (no contrast). Core products include XV LVAS and the newer CT:VQ. Revenue is intended to be per-scan SaaS + service contracts with US health systems.
  • FDA 510(k) clearance (4 Sep 2025) for CT:VQ — first non-contrast V/Q imaging solution cleared in the US.

  • CMS reimbursement confirmed (3 Sep 2025) — CT:VQ mapped to Category III CPT codes 0721T/0722T with US$650.50 per scan, effective immediately. That gives hospitals a payment pathway.

  • Together, these de-risk US commercialization and explain the sharp price spike and new 52-week highs reported around that time.

  • June QTR Cash flow report: Revenue $1.6M | OCF -$9.5M | Cash on hand: $6.9M | No debt

 

 

 


Disclaimer: This information is provided purely for educational purposes. It takes no account of an individual’s personal financial circumstances and hence can in no way constitute financial advice. The above data may be subject to errors or inconsistencies for which the author takes no liability. It is imperative that all investors do their own research or if they need advice, seek it from a qualified financial adviser.

FY25 Results Season Performances

Presentation: When Do I Sell?

In this presentation — When Do I Sell? — I explore why selling is the hardest part of investing. We’ll look at the many reasons investors sell, the common pitfalls we’ve all fallen into, and then I’ll share the framework I use today. I support this with recent examples of stocks I’ve sold, and finish with a look at some of my current holdings and how I’m thinking about potential exit points.

1. Introduction

  • Selling is the hardest decision in investing.

  • Paper trading can’t capture the psychology.

  • Biases: anchoring to entry, waiting for breakeven, falling in love with a story.

  • My biggest past issue: cutting winners too soon.

    • Improved by using a framework + building skill at buying back in when I’ve sold too early.

It’s not about winning every hand. It’s about stacking probabilities. Fold when odds aren’t in your favour and wait for the better hand.


2. Reasons People Sell

(broad, neutral list — not judged, meant to spark recognition)

  • Technical breakdown

    • Falling through support or resistance levels.

    • Overbought / oversold indicators.

    • Moving average crossovers (general).

    • Breakdown of a clear trend.

  • Change in investment thesis

    • Fundamentals shift.

    • Earnings downgrades. 

    • Significant earnings misses.

  • Portfolio reshaping

    • Selling weaker positions to fund higher conviction opportunities.

    • Rebalancing for risk control.

  • Market-driven selling

    • Fear of crashes, recessions, geopolitical shocks.

  • Personal reasons

    • Tax planning.

    • Liquidity needs.

  • Behavioural reasons

    • Chasing another idea.

    • Boredom / story fatigue.

    • Overconfidence in calling tops.

  • Profit-taking

    • Locking in gains.

“You never go broke taking a profit” — first heard this from Rene Rivkin as one of his rules. I’ve come to realise thinking like this cost me a lot of money as it often means cutting winners too soon.

  • Capitulation

    • Selling because you just can’t bear the pain anymore.

This last one, capitulation, is where we cross into pitfalls. When selling shifts from disciplined to emotional.


3. Pitfalls

  • Anchoring to entry price.

  • Waiting for breakeven.

  • Selling too soon (my biggest past issue) – happy with a quick profit.

  • Falling in love with a story/company.

  • Not admitting you’re wrong quickly (and refusing to buy back in).


4. My Framework

  • Multi-period analysis (monthly, weekly, daily alignment).

  • 3EMA crossovers — my consistent technical signal.

  • Fundamental triggers:

    • Change in investment thesis (downgrades/misses).

    • Selling weaker positions to fund stronger conviction ideas.

  • Other indicators I’ve trialled but don’t rely on now:

    • ATR trailing stops.

    • % fall rules.

    • Dollar-loss limits (% of portfolio).


5. Case Studies – some recent sells

BUB

  • Trigger: Technical weakness led to sell and recent unexplained CEO change added risk.

  • Outcome: Stock has slowly continued to trend lower.

  • Lesson: A stricter application of my rules would have captured more profit.

MXO

  • Trigger: Cross of 10 and 21 day EMA.
  • Outcome: Stock has slowly continued to trend lower.
  • Lesson: A stricter application of my rules would have captured more profit.

XRO

  • Trigger: An acquisition that I perceived to be high risk / capital raise putting pressure on the share price / weakening technical picture.
  • Outcome: Stock has continued to trend lower.
  • Lesson: Application of my methodology has saved me from being stuck in falling stock in a rising market.

PME

  • Trigger: change of trend, moving averages crossing below one another.
  • Outcome: stock fell for a few weeks after only to start a new uptrend just above $200
  • Lesson: No regrets. Followed the process which saved me from some sleepless nights for a few weeks. I was aware when the trend turned favourable again and chose not to buy back in having moved on an invested elsewhere.

MRE

Trigger: Conversation with an ASA member that I highly respect

Outcome: I sold but should have done so much sooner

Lesson: Don’t allow my biases to blur my judgement!


6. Portfolio walk-through – when would I sell?

A change in fundamentals – ie shifting from increasing profits to falling profits, a significant fall in earnings, a poorly justified change in leadership or a significant acquisition that I perceive changes the risk profile of the business.

  • DVP – close below 21 day EMA

  • GDG | ZIP | VYS | GNP | CGS | SRV | KYP | TEA  – 10 day EMA crosses below 21 day EMA.
  • RMD – 10 day EMA crosses below 125 day EMA

  • CCL | FWD – have held through a 10 day cross of the 21 day EMA but would likely sell if it happened again to protect profits but would depend when it occurred.
  • SRV → Sold, then re-entered lower.


7. Wrap-Up

Selling is the hardest decision. There are many reasons investors sell — some rational, others emotional traps. My journey has been about moving from cutting winners too early to developing a more disciplined framework. I’m now better at cutting losers, holding winners, and buying back in when I’ve sold too soon. In the end, it’s about consistency and discipline: stacking the odds like in poker, and living to play the next hand.

Over time, consistency and discipline beat emotion.


8. Group Discussion

Prompts:

  • What’s your biggest struggle with selling?

  • Do you recognise yourself in any of these reasons or pitfalls?

  • Do you set sell rules before you buy?

  • Do you buy back in if you think you’ve sold too early?

  • What’s been your best or worst sell?

  • Looking ahead: how do you plan to improve your selling discipline?


Disclaimer: This information is provided purely for educational purposes. It takes no account of an individual’s personal financial circumstances and hence can in no way constitute financial advice. The above data may be subject to errors or inconsistencies for which the author takes no liability. It is imperative that all investors do their own research or if they need advice, seek it from a qualified financial adviser.

Presentation: When Do I Sell?

Forensic Analysis: Findi ASX:FND

📅 July, 2025
🌐 Website: https://findi.co/

Here is a forensic financial analysis of Findi (ASX:FND), based on its FY25 Annual Report (year ended 31 March 2025).

📊 Balance Sheet

Risk Indicator Status Comments
Goodwill >25% of Assets 🔴 Goodwill = $39.7M; Total Assets = $323M → 12% from Tata/BankIT acquisitions, but intangible assets overall ~$62M (19% of total) and rising rapidly.
Rising Receivables Days Receivables grew only slightly (to $8.2M from $8.1M) while revenue increased ~13%. No concerning rise observed.
Inventory Growth vs Profit 🟠 Not Applicable No inventory reported (services business). Not applicable but flagged as 🟠 to note working capital sensitivity to contracts.
High Borrowings 🔴 Total borrowings ~$123M ($85M current), Net Debt rising, finance costs up ~3x ($29.4M), Debt-to-Equity ~1.9x (258M liabilities vs 64M equity).
Loans to Related Parties No material related party loans disclosed beyond normal intra-group balances.
Idle Cash 🟠 ~$115.9M cash balance, but significant earmarked deployment. However, cash held exceeds 18 months of opex without detailed return disclosures.

📈 Income Statement

Risk Indicator Status Comments
Revenue vs Profit Divergence 🔴 Revenue up 13%, but NPAT swung from $4M profit to ($12M) loss driven by finance costs and one-off debenture restructure. Underlying profitability questionable.
Capitalised R&D/Interest No large capitalisation of R&D; most intangible growth is goodwill from acquisitions. No major hidden costs observed.
Extraordinary Items 🔴 $7.2M extraordinary income write-back, improving EBITDA materially. This indicates reliance on non-recurring items.
Tax Rate Drop Effective tax benefit due to losses. No unexplained low tax rate.
Profit vs Cash Flow 🟠 OCF ($17.5M) materially below EBITDA ($33.3M), indicating large working capital/cost drag.
One-Off Gains Boosting Profit 🔴 Write-back of $7.2M provision plus revaluation gains; without these, EBITDA and NPAT would have been weaker.

🏛️ Governance, Disclosure & Audit

Risk Indicator Status Comments
Auditor Changes Hall Chadwick continues as auditor. No recent changes disclosed.
Audit Qualifications Clean audit opinion.
Exec Departures 🟠 CEO change mid-strategy: Mohnish Kumar transitioned to Vice Chairman. No major rationale elaborated.
Transparency Issues 🟠 Extraordinary income and significant transaction impacts disclosed but diluted across notes; segment profitability clarity limited.
Board Weakness Board includes experienced finance professionals and independent directors.
Executive Pay Misalignment 🔴 Chairman remuneration jumped from $150k to $675k amid swinging to losses. Board remuneration >$1.4M while net loss increased.
Promotional Language 🟠 Repeated promotional claims (“transformative milestones,” “unparalleled financial access”) despite poor earnings.

🧠 Strategic Risk Factors

Risk Indicator Status Comments
Chronic Unprofitability 🟠 FY25 loss was primarily transactional, but 3-year profitability track record inconsistent. Loss narrowing uncertain.
Revenue < Capex 🟠 ~$17M capex + ~$75M acquisitions vs $75M revenue; heavy reinvestment phase with unclear payback timelines.
Funding Dependency 🔴 Equity raises in FY25 ($40M placement + SPP), plus debt refinancing. Repeated external funding critical to operations.
Customer Concentration 🟠 Major contracts with State Bank of India, Union Bank, and Central Bank—customer concentration risk likely >50%.
Pre-commercial Product Risk Core business operational with revenue streams; no pure pre-commercial dependence.
Short Cash Runway Cash holdings sufficient for >12 months operations.
Regulatory/Compliance Exposure 🟠 Heavy reliance on RBI licences, acquisition integration risk.
Leadership Turnover During Expansion 🟠 CEO transitioned mid-expansion. Management continuity not fully explained.

✅ Final Summary

Category 🔴 Red Flags 🟠 Amber Flags
Balance Sheet 2 2
Income Statement 3 1
Governance / Disclosure 1 3
Strategic Risk Factors 1 4

🔴 Total Red Flags: 7
🟠 Total Amber Flags: 10


🟠 Amber & 🔴 Red Flag Overview

  • 🔴 High Borrowings: Debt-to-equity approaching 2x with finance costs tripling.

  • 🔴 Extraordinary Items & One-off Gains: $7.2M non-recurring write-back and revaluations masked underlying losses.

  • 🔴 Executive Pay Misalignment: Chairman and board fees rose sharply during a swing to losses.

  • 🔴 Funding Dependency: Equity raises and debenture restructuring are critical to liquidity.

  • 🔴 Revenue vs Profit Divergence: Revenue rose while NPAT fell into loss.

  • 🔴 One-Off Gains Boosting Profit: Extraordinary income contributed materially to reported EBITDA.

  • 🟠 Idle Cash: Large cash holdings without clear disclosure of return strategy.

  • 🟠 OCF vs EBITDA: Cash flow lagged EBITDA significantly.

  • 🟠 Transparency: Disclosures of transaction impacts fragmented across notes.

  • 🟠 Leadership Turnover: CEO transitioned during major expansion.

  • 🟠 Customer Concentration: Dependence on large public sector banks.

  • 🟠 Capex vs Revenue: Heavy investment relative to annual turnover.

  • 🟠 Chronic Unprofitability: Inconsistent profitability trend.

  • 🟠 Regulatory Exposure: Reliant on RBI licences, regulatory compliance critical.

Forensic Analysis: Findi ASX:FND - 12 month daily price chart with 3EMA and volume indicators


Disclaimer: This information is provided purely for educational purposes. It takes no account of an individual’s personal financial circumstances and hence can in no way constitute financial advice. The above data may be subject to errors or inconsistencies for which the author takes no liability. It is imperative that all investors do their own research or if they need advice, seek it from a qualified financial adviser.

Forensic Analysis: Findi ASX:FND